TOPページ
|
英語
日本語
|
CONNECT WITH US:
ホーム
JCNについて
サービス
お問い合わせ
会員企業ログイン
*
ホーム
プレスリリース一覧
China Medical System Holdings Ltd.
プレスリリース一覧
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023
Aug 16, 2024 14:00 JST
On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023.
More info..
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China
Aug 05, 2024 23:00 JST
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA).
More info..
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
Jul 16, 2024 21:00 JST
In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development.
More info..
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
Jun 25, 2024 21:46 JST
On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China.
More info..
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
Jun 18, 2024 19:53 JST
More info..
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
Apr 23, 2024 23:06 JST
More info..
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Apr 01, 2024 21:30 JST
More info..
China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs
Mar 28, 2024 11:29 JST
More info..
China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R)
Feb 04, 2024 10:00 JST
More info..
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA
Jan 02, 2024 15:00 JST
More info..
China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL
Dec 13, 2023 18:36 JST
More info..
China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug
Aug 24, 2023 21:00 JST
More info..
China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management
Jul 31, 2023 21:00 JST
Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices.
More info..
China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China
Jun 12, 2023 21:00 JST
More info..
China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China
May 30, 2023 23:00 JST
On May 30, China Medical System Holdings Limited ("CMS" or the "Group") announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
More info..
CMS Releases Its 2022 Interim Report, Achieves Sustained Growth with Its Platform Strategy
Aug 26, 2022 19:00 JST
More info..
1
新着プレスリリース
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China
2024年09月24日 22時00分
Ainos、限られた治療法しかない希少疾患シェーグレン症候群に対するVELDONAの台湾臨床試験開始計画を発表
2024年09月24日 18時00分
Bumbana Nyami Announces the Launch of Its Game
2024年09月22日 15時00分
Elastos Creates World's First live Music Inscription on Bitcoin at Token 2049
2024年09月20日 22時00分
Seoul Metropolitan Government Intensifies Efforts to Become a Global Top 5 City by Attracting Singaporean Companies
2024年09月20日 14時00分
Silicon FoundryとKearney、「The Collective // Supply Chain」を発表、将来に備えたサプライチェーンの傾向とソリューションの特定を支援
2024年09月19日 22時00分
Ainos、治療法が限られている希少疾患であるシェーグレン症候群の治療薬VELDONAの台湾での臨床試験開始計画を発表
2024年09月19日 21時00分
富士通とSTELLAR SCIENCE FOUNDATION、パートナーシップを締結し、若手研究者支援でイノベーション創出へ
2024年09月19日 18時00分
KKR、富士ソフトに関する公開買付訂正届出書を提出
2024年09月19日 18時00分
Discover Exclusive Italian-Made Luxury Products at FIND - Design Fair Asia 2024
2024年09月17日 21時30分
GobizKOREA Launches the '2024 GobizWEEK Promotion' for International Buyers
2024年09月13日 22時00分
Bringko Announces Its Global Expansion for Korean Top Brands
2024年09月13日 22時00分
9th Belt and Road Summit draws to a successful close
2024年09月13日 09時50分
Honda、「CIVIC」をマイナーモデルチェンジし発売
2024年09月12日 11時00分
MHI-MS、駐車場などでの自動バレーパーキング、完成車自動搬送向け事業展開を加速
2024年09月11日 14時30分
Honda、協調人工知能Honda CIのさらなる進化を目指し、インド工科大学デリー校およびボンベイ校とAI技術の共同研究を開始
2024年09月11日 14時30分
Fast Debt Recovery Specialist Among First Licensed Under Singapore's New Debt Collection Rules
2024年09月11日 10時00分
TRENDE Launches Commercial P2P Energy Trading Service in Partnership with JA Group and ITOCHU
2024年09月10日 16時00分
三菱重工、H-IIAロケット49号機による情報収集衛星レーダ8号機の打上げ延期について
2024年09月09日 16時00分
アリマンタシォン・クシュタール、セブン&アイ・ホールディングスからの回答に対する声明を発表
2024年09月09日 08時00分
もっと見る >>